Yarrow Bioscience (YARW) Accounts Payables (2016 - 2026)
Yarrow Bioscience's (YARW) quarterly Accounts Payables came in at $261000.0 in Q1 2026, down 92.61% YoY from $3.5 million in Q1 2025, and down 74.93% on a QoQ basis from $1.0 million in Q4 2025.
Yarrow Bioscience (YARW) Accounts Payables (2016 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 11 years of Accounts Payables data on file, last reported at $261000.0 in Q1 2026.
- Quarterly Accounts Payables fell 92.61% year-over-year to $261000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $261000.0 (down 92.61% YoY) and the FY2025 annual result came in at $1.0 million, down 61.54% from the prior year.
- Accounts Payables declined to $261000.0 in Q1 2026, from $1.0 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $4.5 million in Q2 2024 to a low of $261000.0 in Q1 2026.
- A 5-year average of $2.2 million and a median of $2.3 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2024 — Accounts Payables surged 456.7% — and 2026, when it tumbled 92.61%.
- Tracing YARW's Accounts Payables over 5 years: stood at $2.4 million in 2022, then slumped by 30.47% to $1.7 million in 2023, then jumped by 63.17% to $2.7 million in 2024, then tumbled by 61.54% to $1.0 million in 2025, then tumbled by 74.93% to $261000.0 in 2026.
- The last three Accounts Payables figures came in at $261000.0 (Q1 2026), $1.0 million (Q4 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - | 614,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 614,000.00 |
| Mar 31, 2026 | 261,000.00 |
| Dec 31, 2025 | 1.04 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Mar 31, 2025 | 3.53 Mn |
| Dec 31, 2024 | 2.71 Mn |
| Sep 30, 2024 | 3.99 Mn |
| Jun 30, 2024 | 4.52 Mn |
| Mar 31, 2024 | 2.80 Mn |
| Dec 31, 2023 | 1.66 Mn |
| Sep 30, 2023 | 716,000.00 |
| Jun 30, 2023 | 1.16 Mn |
| Mar 31, 2023 | 2.21 Mn |
| Dec 31, 2022 | 2.39 Mn |
| Sep 30, 2022 | 2.52 Mn |
| Jun 30, 2022 | 1.43 Mn |
| Mar 31, 2022 | 3.61 Mn |
| Dec 31, 2021 | 6.51 Mn |
| Sep 30, 2021 | 7.62 Mn |
| Jun 30, 2021 | 10.08 Mn |